Self Study Module 2: Evolving Treatment Options in Advanced BCC: Immunotherapy

Launch Date:
November 12, 2021
Expiration Date:
The accreditation for this activity has expired.
Return to Enrollment Page

Primary Audience:

MD, PA, NP

Relevant Terms:

Oncology, Basal Cell Carcinoma

OVERVIEW

Identify patients with advanced BCC who have failed or cannot tolerate hedgehog inhibitor therapy and utilize an interdisciplinary approach to assess treatment options, including PD-1 inhibitors, and develop a plan to prevent/manage treatment-associated adverse events.

FACULTY

Anthony M. Rossi, MD, FAAD 

Dermatologic, Mohs, & Laser Surgery Assistant Attending
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
Assistant Attending
New York Presbyterian Hospital Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Rossi is a dermatologist who specializes in Mohs micrographic surgery and other dermatologic surgeries for the treatment of skin cancers such as melanoma, basal cell carcinoma, and squamous cell carcinoma. 

Vernon K. Sondak, MD

Chair, Department of Cutaneous Oncology, Moffitt Cancer Center,
Tampa, Florida
Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology
Professor, Departments of Oncologic Sciences and Surgery, USF Morsani College of Medicine,
Tampa, Florida

Dr. Sondak is Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He holds the Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology, and is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. 

LEARNING OBJECTIVES

1.
Identify patients for whom hedgehog inhibitor therapy may no longer be viable due to lack of response or adverse events
2.
Summarize pivotal data on the efficacy and safety of PD-1 inhibitors, and their practical implications for treatment selection and AE prevention and management
3.
Apply expert guidance to augment guideline recommendations when determining treatment pathways in patients with advanced BCC  

GENERAL INFORMATION

Supported by an unrestricted educational grant from Regeneron Pharmaceuticals.

TARGET AUDIENCE

This certified CME activity is designed for dermatologists (including Mohs surgeons), dermatology physician assistants and nurse practitioners, and oncologists involved in the care of patients with BCC.

ACCREDITATION STATEMENT

Provided by Evolve Medical Education, LLC (Evolve)

      

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians

Evolve designates this Other (Blended Live and Enduring Curriculum) activity (Gather-ed Curriculum) for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Education

PAs may claim a maximum of 3.0 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

TO OBTAIN CREDIT

Credit will be awarded at the completion of the curriculum, after completing the Post Gathered Assessment. Credit is provided through August 30, 2022

In the event you have questions about this activity or are unable to retrieve the certificate, please email info@evolvemeded.com.

 

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Anthony M. Rossi, MD, FAAD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Allergan. Consultant: Almirall, Biofrontera, Canfield Scientific, Dynamed, Evolus, Lam Therapeutics, Merz, Quantia MD, and Regeneron Pharmaceuticals. Grant/Research Support: Biofrontera, Leo Pharma, and Regeneron Pharmaceuticals. Speaker’s Bureau: Almirall and Biofrontera.

Vernon K. Sondak, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: BMS, Eisai, Merck, Novartis, Regeneron Pharmaceuticals, and Replimune. Grant/Research: Neogene Therapeutics.

The Evolve staff, planners, and peer reviewers have no financial relationships with commercial interests.

 

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindica­tions, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals.